Predictors of late complications in pregnant women with arterial hypertension

Abstract

Arterial hypertension occurs in 8–29% of pregnant women and is a common form of endothelial dysfunction during gestation. In recent decades, the prevalence of arterial hypertension has increased several times largely due to the increasing maternal age of primiparous women and the increased incidence of obesity, diabetes mellitus, and carbohydrate metabolism disorders.

The aim of this study was to formulate the management tactics for pregnant patients with high blood pressure, based on the current understanding of the causes and mechanisms of the disease and the ability to influence the molecular links of pathogenesis, and to identify possible markers for predicting the progression of endothelial dysfunction in pregnant women with arterial hypertension. This review, based on the literature, raises the problem of modern diagnosis of arterial hypertension in pregnancy. We discuss the consequences of late initiation of the therapy and evaluate possible complications.

The severity of arterial hypertension is assessed differently in pregnant and non-pregnant women, according to current clinical guidelines. Thus, chronic arterial hypertension in pregnant women corresponds to grade II arterial hypertension in non-pregnant women, according to the American Heart Association and American College of Cardiology classification. Both untimely diagnosis and delayed or inadequate treatment result in adverse obstetric outcomes. Recent studies indicate the ability of earlier antihypertensive therapy (already at stage I according to the American Heart Association and American College of Cardiology classification) to reduce maternal and fetal adverse effects and prolong pregnancy. The CHAP 2022 study showed that using a blood pressure treatment threshold of 140/90 mmHg for pregnant women with chronic arterial hypertension provides better outcomes compared to treatment at higher numbers. Despite early initiation of therapy, some patients with elevated blood pressure subsequently develop thrombotic and gestational complications associated with endothelial dysfunction. There is an obvious need to introduce early preclinical diagnostic methods that would narrow the risk group and prevent late complications. The authors’ consensus on personalization of acetylsalicylic acid intake has emerged. The review analyzes the potential mechanisms of aspirin resistance, as well as the influence of genetic (the PTGS1, PTGS2, ITGB3, ITGA2, GP6, GP1BA, P2RY1, P2RY12 genes, other genes, and associated microRNA) and biochemical markers (11-dehydrotromboxane B2), which presumably may have prognostic value and applicability in clinical practice.

Our current understanding of the problem of diagnosis and early treatment of arterial hypertension in pregnancy can reduce the number of complications. The problem of predicting the development of endothelial dysfunction remains unresolved to the end. Active implementation of the studied markers into practice requires a further more detailed study of this area and the optimization of research design.

Keywords

arterial hypertension / pregnancy / endothelial dysfunction

References

[1] Ananth CV, Duzyj CM, Yadava S, et al. Changes in the prevalence of chronic hypertension in pregnancy, United States, 1970 to 2010. Hypertension. 2019;74(5):1089–1095. DOI: 10.1161/HYPERTENSIONAHA.119.12968

[2] Ananth C.V., Duzyj C.M., Yadava S, et al. Changes in the prevalence of chronic hypertension in pregnancy, United States, 1970 to 2010 // Hypertension. 2019. Vol. 74. No. 5. P. 1089–1095. DOI: 10.1161/HYPERTENSIONAHA.119.12968

[3] Lecarpentier E, Tsatsaris V, Goffinet F, et al. Risk factors of superimposed preeclampsia in women with essential chronic hypertension treated before pregnancy. PLoS One. 2013;8(5). DOI: 10.1371/journal.pone.0062140

[4] Lecarpentier E., Tsatsaris V., Goffinet F., et al. Risk factors of superimposed preeclampsia in women with essential chronic hypertension treated before pregnancy // PLoS One. 2013. Vol. 8. DOI: 10.1371/journal.pone.0062140

[5] American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. Obstet Gynecol. 2019;133(1):e26–e50. DOI: 10.1097/AOG.0000000000003020

[6] Аmerican College of Obstetricians and Gynecologists, Committee on Practice Bulletins Obstetrics. ACOG practice bulletin No. 203: Chronic hypertension in pregnancy // Obstet. Gynecol. 2019. Vol. 133. No. 1. P. 26–50. DOI: 10.1097/AOG.0000000000003020.

[7] Rossiiskoe obshchestvo akusherov-ginekologov (ROAG), Assotsiatsiya anesteziologov-reanimatologov (AAR), Assotsiatsiya akusherskikh anesteziologov-reanimatologov (AAAR). Preeklampsiya. Eklampsiya. Oteki, proteinuriya i gipertenzivnye rasstroistva vo vremya beremennosti, v rodakh i poslerodovom periode: klinicheskie rekomendatsii. 2021. (In Russ.). [cited 2022 Sept 15]. Available from: https://roag-portal.ru/recommendations_obstetrics

[8] Российское общество акушеров-гинекологов (РОАГ), Ассоциация анестезиологов-реаниматологов (ААР), Ассоциация акушерских анестезиологов-реаниматологов (АААР). Преэклампсия. Эклампсия. Отеки, протеинурия и гипертензивные расстройства во время беременности, в родах и послеродовом периоде: клинические рекомендации. 2021 [дата обращения 15.09.2022]. Доступно по ссылке: https://roag-portal.ru/recommendations_obstetrics

[9] Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97–104. DOI: 10.1016/j.preghy.2014.02.001

[10] Tranquilli A.L., Dekker G., Magee L., el al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP // Pregnancy Hypertens. 2014. Vol. 4. No. 2. P. 97–104. DOI: 10.1016/j.preghy.2014.02.001

[11] Petrov YuA, Chebotareva YuYu, Ovsyannikov VG, et al. Modern aspects of chronic hypertension during pregnancy. Medical Herald of the South of Russia. 2015;(3):5–8. (In Russ.). DOI: 10.21886/2219-8075-2015-3-5-8

[12] Петров Ю.А., Чеботарева Ю.Ю., Овсянников В.Г., и др. Современные аспекты хронической артериальной гипертензии при беременности // Медицинский вестник Юга России. 2015. № 3. C. 5–8. DOI: 10.21886/2219-8075-2015-3-5-8

[13] Sun Y, Yang YL, Yang HX. Maternal and perinatal prognosis of pregnancy with chronic hypertension and analysis of associated factors. Zhonghua Fu Chan Ke Za Zhi. 2007;42(7):434–437.

[14] Sun Y., Yang Y.L., Yang H.X. Maternal and perinatal prognosis of pregnancy with chronic hypertension and analysis of associated factors // Zhonghua Fu Chan Ke Za Zhi. 2007. Vol. 42. No 7. P. 434–437.

[15] Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3). (In Russ.). DOI: 10.15829/1560-4071-2020-3-3786

[16] Кобалава Ж.Д., Конради А.О., Недогода С.В., и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020 // Российский кардиологический журнал. 2020. Т. 25. № 3. DOI: 10.15829/1560-4071-2020-3-378

[17] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the american college of cardiology/American Heart Association Task Force on Clinical Practice. Hypertension. 2018;71(6):1269–1324. DOI: 10.1161/HYP.0000000000000066

[18] Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American // Hypertension. 2018. Vol. 71. No. 6. P. 1269–1324. DOI: 10.1161/HYP.0000000000000066

[19] Greenberg VR, Silasi M, Lundsberg LS, et al. Perinatal outcomes in women with elevated blood pressure and stage 1 hypertension. Am J Obstet Gynecol. 2021;224(5):521.e1–521.e11. DOI: 10.1016/j.ajog.2020.10.049

[20] Greenberg V.R., Silasi M., Lundsberg L.S., et al. Perinatal outcomes in women with elevated blood pressure and stage 1 hypertension // Am. J. Obstet. Gynecol. 2021. Vol. 224. No. 5. DOI: 10.1016/j.ajog.2020.10.049

[21] Darwin KC, Federspiel JJ, Schuh BL, et al. ACC-AHA diagnostic criteria for hypertension in pregnancy identifies patients at intermediate risk of adverse outcomes. Am J Perinatol. 2021;38(1):e249–e255. DOI: 10.1055/s-0040-1709465

[22] Darwin K.C., Federspiel J.J., Schuh B.L., et al. ACC-AHA diagnostic criteria for hypertension in pregnancy identifies patients at intermediate risk of adverse outcomes // Am. J. Perinatol. 2021. Vol. 38. No. 1. P. e249–e255. DOI: 10.1055/s-0040-1709465

[23] Bateman BT, Bansil P, Hernandez-Diaz S, et al. Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. Am J Obstet Gynecol. 2012;206(2):134.e1–134.e1348. DOI: 10.1016/j.ajog.2011.10.878

[24] Bateman B.T., Bansil P., Hernandez-Diaz S., et al. Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions // Am. J. Obstet. Gynecol. 2012. Vol. 206. No. 2. DOI: 10.1016/j.ajog.2011.10.878

[25] Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–1131. DOI: 10.1097/01.AOG.0000437382.03963.88

[26] Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy // Obstet. Gynecol. 2013. Vol. 122. No. 5. P. 1122–1131.

[27] Bramham K, Parnell B, Nelson-Piercy C, et al. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ. 2014;348. DOI: 10.1136/bmj.g2301

[28] Bramham K., Parnell B., Nelson-Piercy C., et al. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis // BMJ. 2014. Vol. 348. DOI: 10.1136/bmj.g2301

[29] Ye C, Ruan Y, Zou L, et al. The 2011 survey on hypertensive disorders of pregnancy (HDP) in China: prevalence, risk factors, complications, pregnancy and perinatal outcomes. PLoS One. 2014;9(6). DOI: 10.1371/journal.pone.0100180

[30] Ye C., Ruan Y., Zou L., et al. The 2011 survey on hypertensive disorders of pregnancy (HDP) in China: prevalence, risk factors, complications, pregnancy and perinatal outcomes // PLoS One. 2014. Vol. 9. No. 6. DOI: 10.1371/journal.pone.0100180

[31] Panaitescu AM, Syngelaki A, Prodan N, et al. Chronic hypertension and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol. 2017;50(2):228–235. DOI: 10.1002/uog.17493

[32] Panaitescu A.M., Syngelaki A., Prodan N., et al. Chronic hypertension and adverse pregnancy outcome: a cohort study // Ultrasound Obstet. Gynecol. 2017. Vol. 50. No. 2. P. 228–235. DOI: 10.1002/uog.17493

[33] Sibai BM, Anderson GD. Pregnancy outcome of intensive therapy in severe hypertension in first trimester. Obstet Gynecol. 1986;67(4):517–522.

[34] Sibai B.M., Anderson G.D. Pregnancy outcome of intensive therapy in severe hypertension in first trimester // Obstet. Gynecol.1986. Vol. 67. No. 4. P. 517–522.

[35] Ramakrishnan A, Lee LJ, Mitchell LE, et al. Maternal hypertension during pregnancy and the risk of congenital heart defects in offspring: a systematic review and meta-analysis. Pediatr Cardiol. 2015;36:1442–1451. DOI: 10.1007/s00246-015-1182-9

[36] Ramakrishnan A., Lee L.J., Mitchell L.E., et al. Maternal hypertension during pregnancy and the risk of congenital heart defects in offspring: a systematic review and meta-analysis // Pediatr. Cardiol. 2015. Vol. 36. P. 1442–1451. DOI: 10.1007/s00246-015-1182-9

[37] Ilic A, Ilic DJ, Tadic S, et al. Influence of non-dipping pattern of blood pressure in gestational hypertension on maternal cardiac function, hemodynamics and intrauterine growth restriction. Pregnancy Hypertens. 2017;10:34–41. DOI: 10.1016/j.preghy.2017.05.003

[38] Ilic A., Ilic D.J., Tadic S., et al. Influence of non-dipping pattern of blood pressure in gestational hypertension on maternal cardiac function, hemodynamics and intrauterine growth restriction // Pregnancy Hypertens. 2017. Vol. 10. P. 34–41. DOI: 10.1016/j.preghy.2017.05.003

[39] Sizova OV, Rad’kov OV, Kolbasnikov SV, et al. Chronic hypertension in pregnant women: prognosis and prevention of pregnancy complications; antihypertensive therapy policy. Russian Bulletin of Obstetrician-Gynecologist. 2018;18(6):25-30. (In Russ.). DOI: 10.17116/rosakush20181806125

[40] Сизова О.В., Радьков О.В., Колбасников С.В., и др. Хроническая артериальная гипертензия у беременных: прогноз и профилактика осложнений гестации, тактика антигипертензивной терапии // Российский вестник акушера-гинеколога. 2018. Т. 18. № 6. С. 25–30. DOI: 10.17116/rosakush20181806125

[41] Chernyavina AI, Surovtseva MV. Impact of polymorphism of cardiovascular risk genes on arterial remodelling development depending on presence of systemic hypertension. Russ J Cardiol. 2018;23(1):43–50. DOI: 10.15829/1560-4071-2018-1-43-50

[42] Чернявина А.И., Суровцева М.В. Вклад полиморфизма генов сердечно-сосудистого риска в развитие артериального ремоделирования в зависимости от наличия артериальной гипертензии // Российский кардиологический журнал. 2018. Т. 23. № 1. С. 43–50. DOI: 10.15829/1560-4071-2018-1-43-50

[43] Holmes L, Lim A, Comeaux CR, et al. DNA methylation of candidate genes (ACE II, IFN-γ, AGTR 1, CKG, ADD1, SCNN1B and TLR2) in essential hypertension: a systematic review and quantitative evidence synthesis. Int J Environ Res Public Health. 2019;16(23). DOI: 10.3390/ijerph16234829

[44] Holmes L. Jr., Lim A., Comeaux C.R., et al. DNA methylation of candidate genes (ACE II, IFN-γ, AGTR 1, CKG, ADD1, SCNN1B and TLR2) in essential hypertension: a systematic review and quantitative evidence synthesis // Int. J. Environ. Res. Public Health. 2019. Vol. 16. No. 23. DOI: 10.3390/ijerph16234829

[45] Stryuk RI, Bunin YuA, Gur’eva VM, et al. Diagnosis and treatment of cardiovascular diseases during pregnancy 2018. National guidelines. Russ J Cardiol. 2018,3(155):91–134 (In Russ.). DOI: 10.15829/1560-4071-2018-3-91-134

[46] Стрюк Р.И., Бунин Ю.А., Гурьева В.М., и др. Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации // Российский кардиологический журнал 2018. Т. 3. № 155. С. 91–134. DOI: 10.15829/1560-4071-2018-3-91-134

[47] Chulkov VS, Vereina NK, Sinitsyn SP, et al. Evaluation of an interrelation of target blood pressure achievement and complications and outcomes of pregnancy in arterial hypertension. Cardiovascular Therapy and Prevention. 2014;13(6):23–27. (In Russ.). DOI: 10.15829/1728-8800-2014-6-23-27

[48] Чулков В.С., Верина Н.К., Синицын С.П. и др. Оценка взаимосвязи достижения целевого артериального давления с осложнениями и исходами беременности при артериальной гипертензии // Кардиоваскулярная терапия и профилактика. 2014. № 6. С. 23–27. DOI: 10.15829/1728-8800-2014-6-23-27

[49] Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007;(1). DOI: 10.1002/14651858.CD002252.pub2

[50] Abalos E., Duley L., Steyn D.W. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy // Cochrane Database Syst. Rev. 2007. Vol. 1. DOI: 10.1002/14651858.CD002252.pub2

[51] Jiang N, Liu Q, Liu L, et al. The effect of calcium channel blockers on prevention of preeclampsia in pregnant women with chronic hypertension. Clin Exp Obstet Gynecol. 2015;42(1):79–81.

[52] Jiang N. The effect of calcium channel blockers on prevention of preeclampsia in pregnant women with chronic hypertension // Clin. Exp. Obstet. Gynecol. 2015. Vol. 42. No. 1. Р. 79–81.

[53] Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6–31. DOI: 10.26442/2075082X.2019.1.190179

[54] Чазова И.Е., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии // Системные гипертензии. 2019. Т. 16. № 1. C. 6–31. DOI: 10.26442/2075082X.2019.1.190179

[55] Magee LA, von Dadelszen P, Singer J, et al. The CHIPS randomized controlled trial (control of hypertension in pregnancy study): is severe hypertension just an elevated blood pressure? Hypertension. 2016;68(5):1153–1159. DOI: 10.1161/HYPERTENSIONAHA.116.07862

[56] Magee L.A., von Dadelszen P., Singer J., et al. The CHIPS randomized controlled trial (control of hypertension in pregnancy study): is severe hypertension just an elevated blood pressure? // Hypertension. 2016. Vol. 68. No. 5. P. 1153–1159. DOI: 10.1161/HYPERTENSIONAHA.116.07862

[57] Аhn HK, Nava-Ocampo AA, Han JY, et al. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. Hypertens Pregnancy. 2007;26(2):179–187. DOI: 10.1080/10641950701204554

[58] Аhn H.K., Nava-Ocampo A.A., Han J.Y., et al. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding // Hypertens Pregnancy. 2007. Vol. 26. No. 2. P. 179–187. DOI: 10.1080/10641950701204554

[59] Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183(1):S1–S22.

[60] Report of the national High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy // Am. J. Obstet. Gynecol. 2000. Vol. 183. P. 1–22. DOI: 10.1016/S0002-9378(00)40820-3

[61] De Swiet M. Maternal blood pressure and birthweight. Lancet. 2000;355(9198):81–82. DOI: 10.1016/s0140-6736(99)00288-3

[62] De Swiet M. Maternal blood pressure and birthweight // Lancet. 2000. Vol. 355. No. 9198. P. 81–82. DOI: 10.1016/s0140-6736(99)00288-3

[63] Kernaghan D, Duncan AC, McKay GA. Hypertension in pregnancy: a review of therapeutic options. Obstet Med. 2012;5(2):44–49. DOI: 10.1258/om.2011.110061

[64] Kernaghan D., Duncan A.C., McKay G.A. Hypertension in pregnancy: a review of therapeutic options // Obstet. Med. 2012. Vol. 5. No. 2. P. 44–49. DOI: 10.1258/om.2011.110061

[65] Braunthal S, Brateanu A. Hypertension in pregnancy: pathophysiology and treatment. SAGE Open Med. 2019;7. DOI: 10.1177/2050312119843700

[66] Braunthal S, Brateanu A. Hypertension in pregnancy: pathophysiology and treatment // SAGE Open Med. 2019. Vol. 7. DOI: 10.1177/2050312119843700

[67] Chistiakova GN, Remizova II, Bychkova SV, et al. Features of the functional activity of endothelium in pregnant women with hypertensive disorders and their newborn children. Russian Journal of Human Reproduction. 2020;26(1):95-103. (In Russ.). DOI: 10.17116/repro20202601195

[68] Чистякова Г.Н., Ремизова И.И., Бычкова С.В. и др. Особенности функциональной активности эндотелия у беременных женщин с гипертензивными расстройствами и их новорожденных детей // Проблемы репродукции. 2020. Т. 26. № 1. С. 95–103. DOI: 10.17116/repro20202601195

[69] Cui Y, Zhu B, Zheng F. Low-dose aspirin at ≤16 weeks of gestation for preventing preeclampsia and its maternal and neonatal adverse outcomes: a systematic review and meta-analysis. Exp Ther Med. 2018;15(5):4361–4369. DOI: 10.3892/etm.2018.5972

[70] Cui Y., Zhu B., Zheng F. Low-dose aspirin at ≤16 weeks of gestation for preventing preeclampsia and its maternal and neonatal adverse outcomes: A systematic review and meta-analysis // Exp. Ther. Med. 2018. Vol. 15. No. 5. Р. 4361–4369. DOI: 10.3892/etm.2018.5972

[71] Roberge S, Sibai B, McCaw-Binns A, et al. Low-dose aspirin in early gestation for prevention of preeclampsia and small-for-gestational-age neonates: meta-analysis of large randomized trials. Am J Perinatol. 2016;33(8):781–785. DOI: 10.1055/s-0036-1572495

[72] Roberge S., Sibai B., McCaw-Binns A. Low-dose aspirin in early gestation for prevention of preeclampsia and small-for-gestational-age neonates: meta-analysis of large randomized trials // Am. J. Perinatol. 2016. Vol. 33. No. 8. Р. 781–785. DOI: 10.1055/s-0036-1572495

[73] Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101(10):1206–1218. DOI: 10.1161/01.cir.101.10.1206

[74] Awtry E.H., Loscalzo J. Aspirin // Circulation. 2000. Vol. 101. No. 10. P. 1206–1218. DOI: 10.1161/01.cir.101.10.1206

[75] Dubrovina SO, Muzalchanova YuS, Vasil’eva VV. Early prediction of preeclampsia (a review). Russian Journal of Human Reproduction. 2018;24(3):67-73. (In Russ.). DOI: 10.17116/repro201824367

[76] Дубровина С.О., Муцалханова Ю.С., Васильева В.В. Раннее прогнозирование преэклампсии (обзор литературы) // Проблемы репродукции. 2018. Т. 2. № 3. С. 67–73. DOI: 10.17116/repro201824367

[77] Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367(9510):606–617. DOI: 10.1016/S0140-6736(06)68040-9

[78] Hankey G.J., Eikelboom J.W. Aspirin resistance // Lancet. 2006. Vol. 367. No. 9510. P. 606-617. DOI: 10.1016/s0140-6736(06)68040-9

[79] Lukianets KYu, Pchelin IYu. Acetylsalicylic acid resistance: risk factors, mechanisms, diagnostic tests. Juvenis Scientia. 2020;6(2):16–34. (In Russ.). DOI 10.32415/jscientia_2020_6_2_16-34

[80] Лукьянец К.Ю., Пчелин И.Ю. Резистентность к терапии препаратами ацетилсалициловой кислоты: факторы риска, механизмы, методы диагностики // Juvenis scientia. 2020. № 2. C. 16–34. DOI: 10.32415/jscientia_2020_6_2_16-34

[81] Jia W, Jia Q, Zhang Y, et al. Association between insulin resistance and aspirin or clopidogrel resistance in Chinese patients with recent ischemic stroke/TIA. Neurol Res. 2021;43(5):406–411. DOI: 10.1080/01616412.2020.1866371

[82] Jia W., Jia Q., Zhang Y., Association between insulin resistance and aspirin or clopidogrel resistance in Chinese patients with recent ischemic stroke // Neurol. Res. 2021. Vol. 43. No. 5. P. 406-411. DOI: 10.1080/01616412.2020.1866371

[83] Ferreira M, Freitas-Silva M, Assis J., et al. The emergent phenomenon of aspirin resistance: insights from genetic association studies. Pharmacogenomics. 2020;21(2):125–140. DOI: 10.2217/pgs-2019-0133

[84] Ferreira M., Freitas-Silva M., Assis J., et al. The emergent phenomenon of aspirin resistance: insights from genetic association studies // Pharmacogenomics. 2020. Vol. 21. No. 2. P. 125–140. DOI: 10.2217/pgs-2019-0133

[85] Bush WS, Moore JH. Chapter 11: Genome-wide association studies. PLoS Comput Biol. 2012;8(12). DOI: 10.1371/journal.pcbi.1002822

[86] Bush W.S., Moore J.H. Chapter 11: Genome-wide association studies // PLoS Comput Biol. 2012. Vol. 8. No. 12. DOI: 10.1371/journal.pcbi.1002822

[87] Maree AO, Curtin RJ, Chubb A, et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost. 2005;3(10):2340–2345. DOI: 10.1111/j.1538-7836.2005.01555.x

[88] Maree A., Curtin R., Chubb A., et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin // J. Thromb. Haemost. 2005. Vol. 3. No. 10. P. 2340–2345. DOI: 10.1111/j.1538-7836.2005.01555.x

[89] Sharma V, Kaul S, Al-Hazzani A, et al. Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis. 2013;35(1):95–99. DOI: 10.1007/s11239-012-0777-8

[90] Sharma V., Kaul S., Al-Hazzani A., et al. Association of COX-2 rs20417 with aspirin resistance // Thromb. Thrombolysis. 2013. Vol. 35. No. 1. P. 95–99. DOI: 10.1007/s11239-012-0777-8

[91] Cooke GE, Liu-Stratton Y, Ferketich AK, et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol. 2006;47(3):541–546. DOI: 10.1016/j.jacc.2005.09.034

[92] Cooke G.E., Liu-Stratton Y., Ferketich A.K., et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination // Am. Coll. Cardiol. 2006. Vol. 47. No. 3. P. 541–546. DOI: 10.1016/j.jacc.2005.09.034

[93] Du G, Lin Q, Wang J. A brief review on the mechanisms of aspirin resistance. Int J Cardiol. 2016;220:21–26. DOI: 10.1016/j.ijcard.2016.06.104

[94] Du G., Lin Q., Wang J. A brief review on the mechanisms of aspirin resistance // Int. J. Cardiol. 2016. Vol. 220. P. 21–26.

[95] Luo GP, Ni B, Yang X, et al. von Willebrand factor: more than a regulator of hemostasis and thrombosis. Acta Haematol. 2012;128(3):158–169. DOI: 10.1159/000339426

[96] Luo G.P., Ni B., Yang X., et al. von Willebrand factor: more than a regulator of hemostasis and thrombosis // Acta Haematol. 2012. Vol. 128. No. 3. P. 158–169. DOI: 10.1159/000339426

[97] Würtz M, Lordkipanidzé M, Grove EL. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. J Thromb Haemost. 2013;11(9):1627–1639. DOI: 10.1111/jth.12318

[98] Wurtz M., Lordkipanidzé M., Grove E. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists // Thromb. Haemost 2013. Vol. 11. No. 9. P. 1627–1639. DOI: 10.1111/jth.12318

[99] Lordkipanidzé M, Diodati JG, Palisaitis DA, et al. Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb Res. 2011;128(1):47–53. DOI: 10.1016/j.thromres.2011.02.019

[100] Lordkipanidzé M., Diodati J.G., Palisaitis D.A., et al. Genetic determinants of response to aspirin: appraisal of 4 candidate genes // Thromb. Res. 2011. Vol. 128. No. 1. P. 47–53. DOI: 10.1016/j.thromres.2011.02.019

[101] Patent RF na izobretenie 2015113953/15 / 16.04.2015. Bjul. No. 32. Chukaeva II, Khachirova AI, Akhmatova FD, et al. Sposob prognozirovaniya aspirinoreistentnosti. (In Russ.). [cited 11.09.2022]. Available from: https://patenton.ru/patent/RU2602664C1.pdf

[102] Патент РФ на изобретение № 2015113953/15 / 16.04.2015. Бюл. № 32. Чукаева И.И., Хачирова А.И., Ахматова Ф.Д., Аронов Л.С., и др. Способ прогнозирования аспиринореистентности [дата обращения 11.09.2022]. Доступно по ссылке: https://patenton.ru/patent/RU2602664C1.pdf

[103] Eyileten C, Wicik Z, De Rosa S, et al. MicroRNAs as diagnostic and prognostic biomarkers in ischemic stroke — a comprehensive review and bioinformatic analysis. Cells. 2018;7(12). DOI: 10.3390/cells7120249

[104] Eyileten C., Wicik Z., De Rosa S., et al. MicroRNAs as diagnostic and prognostic biomarkers in ischemic stroke — a comprehensive review and bioinformatic analysis // Cells. 2018. Vol. 7. No. 12. DOI: 10.3390/cells7120249

[105] Czajka P, Fitas A, Jakubik D, et al. MicroRNA as potential biomarkers of platelet function on antiplatelet therapy: a review. Front Physiol. 2021;12. DOI: 10.3389/fphys.2021.652579

[106] Czajka P., Fitas A., Jakubik D., et al. MicroRNA as potential biomarkers of platelet function on antiplatelet therapy: a review // Front Physiol. 2021. Vol. 12. DOI: 10.3389/fphys.2021.652579

[107] Liu WW, Wang H, Chen XH, et al. miR-34b-3p May promote antiplatelet efficiency of aspirin by inhibiting thromboxane synthase expression. Thromb Haemost. 2019;119(9):1451–1460. DOI: 10.1055/s-0039-1692681

[108] Liu W.W., Wang H., Chen X. H., et al. miR-34b-3p may promote antiplatelet efficiency of aspirin by inhibiting thromboxane synthase expression // Thromb. Haemost. 2019. Vol. 119. No. 9. P. 1451–1460. DOI: 10.1055/s-0039-1692681

[109] Osman A, Fälker K. Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes. Platelets. 2011;22(6):433–441. DOI: 10.3109/09537104.2011.560305

[110] Osman A., Fälker K. Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes // Platelets. 2011. Vol. 22. No. 6. P. 433–441. DOI: 10.3109/09537104.2011.560305

[111] Haneklaus M, Gerlic M, O’Neill LA, et al. miR-223: infection, inflammation and cancer. J Intern Med. 2013;274(3):215–226. DOI: 10.1111/joim.12099

[112] Haneklaus M., Gerlic M., O’Neill L.A.J., et al. miR-223: infection, inflammation and cancer // Intern. Med. 2013. Vol. 274. No. 3. P. 215–226. DOI: 10.1111/joim.12099

[113] de Boer HC, van Solingen C, Prins J, et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J. 2013;34(44):3451–3457. DOI: 10.1093/eurheartj/eht007

[114] de Boer H.C., van Solingen C., Prins J., et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease // Eur. Heart. 2013. Vol. 34. No. 44. P. 3451–3457. DOI: 10.1093/eurheartj/eht007

[115] Kok MG, Mandolini C, Moerland PD, et al. Low miR-19b-1-5p expression in isolated platelets after aspirin use is related to aspirin insensitivity. Int J Cardiol. 2016;203:262–263. DOI: 10.1016/j.ijcard.2015.10.098

[116] Kok M.G., Mandolini C., Moerland P.D., et al. Low miR-19b-1-5p expression in isolated platelets after aspirin use is related to aspirin insensitivity // Int. J. Cardiol. 2016. Vol. 203. P. 262–263. DOI: 10.1016/j.ijcard.2015.10.098

[117] Zufferey A, Ibberson M, Reny JL, et al. New molecular insights into modulation of platelet reactivity in aspirin-treated patients using a network-based approach. Hum Genet. 2016;135(4):403–414. DOI: 10.1007/s00439-016-1642-1

[118] Zufferey A., Ibberson M., Reny J.-L., et al. New molecular insights into modulation of platelet reactivity in aspirin-treated patients using a network-based approach // Hum. Genet. 2016. Vol. 135. P. 403–414. DOI: 10.1007/s00439-016-1642-1

[119] Binderup HG, Houlind K, Madsen JS, et al. Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width. Clin Biochem. 2016;49(15):1167–1172. DOI: 10.1016/j.clinbiochem.2016.04.017

[120] Binderup H.G., Houlind K., Madsen J.S., et al. Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width // Clin. Biochem. 2016. Vol. 49. P. 1167–1172. DOI: 10.1016/j.clinbiochem.2016.04.017

RIGHTS & PERMISSIONS

Khalenko V.V., Arzhanova O.N., Mozgovaya E.V.